CURX
Curanex Pharmaceuticals Inc (NASDAQ)
Healthcare — Biotechnology
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.
None
$0.20
+ (+0.49%)
Sign in to add CURX to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $7.77M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-0.02 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -85.25% |
| Debt/Equity | 155.99 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 34.3 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $9.18 |
| 52-Week Low | $0.26 |
| 50-Day Avg | $0.33 |
| 200-Day Avg | $0.54 |
| Avg Volume | 88.9K |
| Volume | 134.8K |
Performance Analysis
NEUTRALCURX presents a mixed picture with both positive and negative indicators.
+
Trading near its 52-week low ($0.26), which could present a value opportunity.
~
RSI at 34.3 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:05 UTC
Back to Screener Export Report